SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases ...

Massachusetts Financial Services Co. MA lifted its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 20.2% during the 3rd quarter, Holdings Channel reports. The firm ...

J.P. Morgan said its top biotech picks for 2025 were Vertex, Travere, SpringWorks, PTC Therapeutics, Wave Life Sciences, ...

Mutual of America Capital Management LLC trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free ...

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

In a report released on November 19, Anupam Rama from J.P. Morgan maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report), ...

In this article, we’re going to talk about the 12 NASDAQ stocks with biggest upside potential according to analysts. Potomac ...

Fintel reports that on November 20, 2024, Evercore ISI Group initiated coverage of SpringWorks Therapeutics (NasdaqGS:SWTX) ...

Springworks Therapeutics (SWTX – Research Report) received a Buy rating and a $60.00 price target from Evercore ISI analyst Cory Kasimov today.

On Friday, SpringWorks Therapeutics Inc (SWTX) stock saw a decline, ending the day at $36.45 which represents a decrease of $-0.10 or -0.27% from the prior close of $36.55. The stock opened at $36.5 ...

On Thursday, SpringWorks Therapeutics Inc (SWTX) stock saw a modest uptick, ending the day at $36.55 which represents a slight increase of $1.84 or 5.30% from the prior close of $34.71. The stock ...

Buy SWTX near 36.28 target 44.79 stop loss @ 36.18 Details The technical summary data tells us to buy SWTX near 36.28 with an upside target of 44.79. This data also tells us to set a stop loss @ 36.18 ...